Category Archives: Lexaria Bioscience Corp. LXRP

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Covered in November ‘Let’s Toke Business’ Report Alongside Canopy Growth (TSX: WEED)

November 13, 2017

 

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has been featured in the November issue of ‘Let’s Toke Business.’ The report draws similarities between Lexaria and Canopy Growth (TSX: WEED), as both companies have had major breakouts on the stock market recently. The ability of Lexaria’s technology to expand into other markets was mentioned in the report, as well the possibility that non-cannabis applications could demonstrate an even greater potential. On November 9, Lexaria announced that it filed a new patent application with the U.S. Patent and Trademark Office (“USPTO”) covering the use of its DehydraTECH™ technology for the delivery of phosphodiesterase type 5 (PDE5) inhibitors. Based on existing research with cannabinoid delivery, Lexaria believes that its patented DehydraTECH™ technology will enable faster-acting treatments in many cases utilizing lower dosage quantities.

To learn more, visit www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Filing of New Patent Application with USPTO

November 9, 2017

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it has filed a new patent application with the U.S. Patent and Trademark Office (“USPTO”) covering the use of its DehydraTECH™ technology for the delivery of phosphodiesterase type 5 (PDE5) inhibitors. Existing products occupying this space include Viagra™ (sildenafil) and Cialis™ (tadalafil). Per the update, a common complaint regarding existing PDE5 inhibitors relates to the slow-acting nature of the substances. Lexaria believes that its patented DehydraTECH™ technology, building on existing research with cannabinoid delivery, will allow for faster-acting treatments in many cases utilizing lower dosage quantities. Separately, Lexaria this morning announced that a number of existing stock options and warrants have been exercised, with the company receiving a total of $69,736.50 from the transaction.

To view the full press release, visit http://dtn.fm/PcwQ6

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaBioscience.com

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Boosts Revenue by Out-Licensing Patented Technology to Third-Party Partners

November 8, 2017

  • High-margin licensing royalties of 5-10% of gross sales of its patented bioscience technology and process are an attractive valuation builder; LXRP sees more licensing opportunities in 2018
  • LXRP’s technology is patented in the U.S. and Australia; company has national/regional filings pending in 44 countries

Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) generates revenue by out-licensing its patented global technology related to ingestion of edible cannabinoids at a rate of 5-10% of gross sales to its third-party partners. LXRP has also expanded its process of improved and faster inhalation by the body of fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) in pain medications, and even nicotine, a good example of bioabsorption breakthrough technology (http://dtn.fm/ssLY4). LXRP is now positioned to license its technology to tobacco giants and major drug companies, as well as cannabinoid biopharmaceutical companies.

As a result, LXRP sees new business opportunities in 2018. The company is now positioned to out-license — at a high royalty rate — its intellectual property (IP) to biopharmaceutical companies as a partner rather than a competitor, working with other companies, including cannabinoid edible producers, instead of competing with them.

An R&D-driven company, LXRP is disrupting the global industry by specializing in the ingestion of edible forms of cannabinoids. Its technology and process platform offers more rapid forms of delivery and intestinal absorption of orally-taken cannabinoids, vitamins, nicotine and non-steroidal inflammatory drugs. Its patented process not only improves the body’s absorption of edible cannabinoids; it also masks taste, reduces by roughly 75% the time of onset, and increases bio-absorption by 5-10x. The company has secured patents related to its processing technology in the U.S. and Australia, and it has a portfolio of some 19 national/regional patent application filings in some 44 countries (http://dtn.fm/Y6ekx).

Primarily a B2B company, LXRP also makes for demonstration purposes branded consumer products under the ViPova™, Lexaria Energy Foods, and TurboCBD™ brands. It recently acquired the remaining 49% of its majority owned Poviva Tea LLC subsidiary (http://dtn.fm/G3vKs). It now owns 100% ownership interest, reaffirming its commitment to the ViPova product lines, as noted by the company in a recent news release.

Separately, in financial news, LXRP has extended the date of its warrants issued on January 19, 2017, to expire on January 19, 2019. The exercise price and the quantity of the warrants has not changed, it said in a 8K SEC filing. LXRP, in its corporate presentation, said that the next round of capital investment is expected to be in “plant to bloodstream” companies, such as itself.

For more information, visit the company’s website at www.LexariaBioscience.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Enters the Multibillion-Dollar Tea Market

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed delivery technologies to improve absorption of bioactive compounds and intends to use that technology in the tea market. The company plans to apply its patented DehydraTECH™ technology to supplement a range of black teas with cannabidiol (CBD) from hemp. An article discussing this reads: “Lexaria’s acquisition of Poviva Tea, LLC, announced on November 2 (http://dtn.fm/lXWr8), gives Lexaria a toehold in this vast $7 billion-plus market and consolidates ownership of Poviva Tea, LLC as a wholly owned Lexaria Bioscience subsidiary. The move also simplifies future operations and certain intellectual property ownership issues. In addition, Lexaria announced that, effectively immediately, PoViva Tea will now operate with the trade name of ViPovaTM Tea. The company believes that the rebranding will ensure long-term protection of intellectual rights. At the center of this strategy is Lexaria’s patented DehydraTECH technology, which is focused on improving the delivery of many commonly used Active Pharmaceutical Ingredients (APIs). The DehydraTECH technology provides an additional layer of effectiveness, designed to harmonize with the intellectual property of third parties, which both patented and generic API substances can employ. Lexaria’s long term strategy is to partner with the world’s leading firms as they deliver best-of-class products to their existing large consumer groups.”

To view the full article, visit http://dtn.fm/L3rXu

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaEnergy.com

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Supplements Popular Beverage with Legal CBD

November 7, 2017

  • Unique patented drug delivery platform
  • Active in world’s largest beverage market
  • Technology that compliments rather than competes with CBD companies

An old and popular beverage is being supplemented in a healthy, flavorful way now that Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is on the scene. Having increased its ownership stake in PoViva Tea, LLC from 51% to 100%, the innovative drug delivery biotech plans to apply its patented DehydraTECH™ technology to supplement a range of black teas with cannabidiol (CBD) from hemp. After water, tea is the most widely consumed beverage in the world and is an ideal adjuvant to speed adoption of CBD supplements. Now that it is complementing the recognized virtues of tea with the therapeutic benefits of CBD, Lexaria is poised to revolutionize the age-old ritual of afternoon tea.

America is a nation of tea drinkers. In 2016, Americans drank 84 billion cups of tea; that is 260 cups for every man, woman and child. Of the 3.8 billion gallons thus consumed, about 80% was black tea, 16% was green tea, while the rest was either Oolong, white or dark tea. Unlike the rest of the world, Americans like their tea cold. About 80 percent of the tea consumed on a daily basis is chilled. However, hot tea appears to be gaining in popularity with the health conscious. The Tea Association of the USA reports (http://dtn.fm/4lDBE) that ‘total category sales for hot tea have increased more than 15% over the last 5 years…’ The Association ‘anticipates strong, continuous growth, with a CAGR of 4-6% (coming) from all segments driven by variety, convenience, health benefits, sustainability, availability, continued innovation and the discovery of unique, flavorful and high-end specialty teas’.

Lexaria’s acquisition of Poviva Tea, LLC, announced on November 2 (http://dtn.fm/My4oq), gives Lexaria a toehold in this vast $7 billion plus market and consolidates ownership of Poviva Tea, LLC as a wholly owned Lexaria Bioscience subsidiary. The move also simplifies future operations and certain intellectual property ownership issues. In addition, Lexaria announced that, effectively immediately, PoViva Tea will now operate with the trade name of ViPovaTM Tea. The company believes that the rebranding will ensure long-term protection of intellectual rights. At the center of this strategy is Lexaria’s patented DehydraTECH technology, which is focused on the improving the delivery of many commonly used Active Pharmaceutical Ingredients (APIs). The DehydraTECH technology provides an additional layer of effectiveness, designed to harmonize with the intellectual property of third parties, which both patented and generic API substances can employ. Lexaria’s long term strategy is to partner with the world’s leading firms as they deliver best-of-class products to their existing large consumer groups.

Lexaria is constantly exploring ways to make the health benefits of cannabinoids (CBD) more accessible and the company’s DehydraTECH technology is a way to do so. Many hemp products on the market are simply mixtures of hemp oil with other ingredients. However, Lexaria’s patented methodology infuses organically sourced hemp oil into the molecules of other substances, such as lipids, which, as it turns out, form the basis of the human endocannabinoid system. Consequently, the body better absorbs products employing the technology.

Presently, Lexaria is the only company in the world that has been awarded a patent for the improved (oral or ingestible, including pills) delivery of all non-psychoactive cannabinoids. Patents have been awarded in the U.S. and Australia and are pending in 40 more countries. This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs.

Lexaria is already applying its innovative delivery technology to the range of ViPova black teas, which come from the province of Yunnan in China and are supplemented with hemp oil infused within dried evaporated non-fat milk. Introduced in January 2015, the tea is available in a variety of varieties and flavors. The ViPova range runs from 8 to 32 bag portions and varieties include Decaf English Breakfast, Earl Grey, Herbal Bengal Chai, Herbal Cherry Black Tea, Herbal Masala Chai, Low-Caf Organic Evening Green Tea and ViPova Light.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Acquisition of 100% Ownership Interest in Poviva Tea, LLC

November 2, 2017

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it has acquired 100 percent ownership interest in its majority owned subsidiary, Poviva Tea, LLC. Lexaria previously owned 51 percent interest in Poviva Tea. “This acquisition strengthens Lexaria’s intellectual property positioning and we reaffirm our commitment to the ViPova Tea product lines,” Chris Bunka, chief executive officer of Lexaria, stated in the news release. “Lexaria thanks the founders of Poviva Tea, LLC for their assistance and vision in this transaction.” Per the update, compensation related to this acquisition was $70,000 in the form of a waiver on certain debts and a five percent, 20-year royalty on net profits related to ViPova Tea™, coffee and hot chocolate sales. No Lexaria stock or options were issued.

To view the full press release, visit http://dtn.fm/oxB6V

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaBioscience.com

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Receives Extensive Patent Allowance from USPTO

November 1, 2017

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a drug delivery platform innovator, announced late yesterday that it has received a new Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) related to the use of its innovative DehydraTECH™ technology as a delivery platform for the full list of active pharmacological ingredients requested, including all cannabinoids, fat-soluble vitamins, nonsteroidal anti-inflammatory pain medications (“NSAIDs”) and nicotine. The company expects formal patent issuance within three to four months, with provided protections extending through 2035 or later. “This wide-ranging patent allowance from the USPTO exceeds our expectations,” Chris Bunka, chief executive officer of Lexaria, stated in the news release. “This vastly expanded intellectual property protection will enable us to aggressively pursue new business opportunities in 2018 such as what could be the world’s first nicotine edibles for the smokeless tobacco industry, or enhanced products for NSAID-derived pain management, as well as in the rapidly growing cannabis market.”

To view the full press release, visit http://dtn.fm/6jl5T

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.lexariabioscience.com

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) to Hold Web-Meeting on November 1

October 20, 2017

  • Web-meeting scheduled for November 1, 2017, at 4:15 p.m. ET
  • 19 patents filed encompassing 44 countries
  • Patents cover broad range of lipophilic bio-actives including cannabinoids, vitamins and other pharma
  • Patented lipophilic delivery system proven to improve bio-absorption

The medical effectiveness of cannabinoids is no longer in question, and the cannabinoid market proliferates ever faster as more people realize the therapeutic benefits. However, the human gastrointestinal tract just doesn’t absorb cannabinoids effectively, and much of what is ingested is subsequently excreted by the body, causing onset times and efficacy to vary wildly.

With 19 patent applications filed internationally covering 44 countries, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has already been issued patents in the U.S. and Australia for the delivery of all non-psychoactive cannabinoids, immediately adding value and validation to the underlying science. Lexaria’s technology is a novel drug delivery platform believed to be applicable across a wide range of different drug types and vitamins, as well as cannabinoids. Lexaria’s lipophilic enhancement technology has been proven to increase both absorption and bioavailability of payload molecules, and the applications and implications are immense.

To clearly communicate this opportunity, Lexaria will host a web-meeting on November 1, 2017, at 4:15 p.m. ET. Lexaria will deliver all the latest news, and, as stated in its newsletter, the company is “expecting to have a LOT to talk about – don’t miss this!” The meeting is open to everyone, but pre-registration is required.

REGISTER here for this important event: https://events.genndi.com/register/169105139238467429/ce8311a9b6

The newsletter also emphasized the fact that Lexaria’s “technology is a delivery platform believed to be applicable to many different types of drugs, vitamins and other substances. It is the applicability of our tech in delivering a substance more efficiently that provides its most substantive value…” To expedite its value proposition, Lexaria has already instructed its attorneys to accelerate examinations of its multiple patent applications wherever possible.

Keeping with strategy, Lexaria is working on several parallel paths toward development of new products and new applications for its technology and seeking new technologies that complement its lipophilic delivery platform. Broad ranging applications will further feed Lexaria’s low-cost, high-margin license and royalty business model of revenue generation. The company’s first licensee is gaining considerable market traction utilizing and paying for its technology, and, with multiple royalty agreements already in the works, Lexaria should easily continue to expand its licensing network. Lexaria has no debt and maintains a healthy cash balance. The company believes it has sufficient cash to follow through with all of the expected R&D and product development, as well as to fund general corporate needs through to the end of 2018.

Lexaria’s novel lipophilic enhancement technology has implications across a wide swath of consumer and pharmaceutical delivery protocols. The global impact of Lexaria’s patented delivery system has barely begun, and it could quickly reverberate to the bottom line.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral Digestion Technology Needs No Sugar Coating

October 12, 2017

  • Delivery technology with application to all non-psychoactive cannabinoids
  • Company is an enabler rather than competitor to hemp oil producers
  • Revenue from licensing DehydraTECH oral digestion technology

Thanks to Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), there’s no need for a spoonful of sugar to help the medicine go down. This innovative biotech has developed technology that masks the strong taste and odor of hemp oil products, eschewing the need for artificial sweeteners, which tend to come with their own fallout to heart and health. Lexaria’s DehydraTECH oral digestion technology is a ‘back office’ process that solves the taste and odor issues that confront all hemp oil producers. With the hemp oil market set to grow 38 percent annually for the near future, Lexaria is well positioned to benefit from the expansion as an enabler rather than competitor. The company intends to license its technology to hemp oil producers, whose numbers continue to rise, and has already tightened its grip on the market with a number of patent filings and registrations.

Hemp might be palatable to a troglodyte, but since it ‘tastes like a handful of grass and dirt’, according to the ‘Made by Hemp’ blog (http://dtn.fm/y1OII), a modern homo sapien, accustomed to his burger and fries, is unlikely to find it palatable. The obvious solution is to complement the intake of hemp with sugars or sweeteners. However, while sugars occurring naturally in fruits and other foods will usually pose no health problem, processed sugar and artificial sweeteners are quite the opposite. “Refined, concentrated sugar consumed in large amounts rapidly increases blood glucose and insulin levels, increases triglycerides, inflammatory mediators and oxygen radicals, and with them, the risk for diabetes, cardiovascular disease and other chronic illnesses,” according to Harvard Health (http://dtn.fm/UhVt0). Moreover, artificial sweeteners can be addictive. One pre-clinical study worryingly demonstrated that rodents, when given a choice between intravenous cocaine and oral saccharine, mostly chose the saccharine.

The prospects for Lexaria’s DehydraTECH technology are decidedly upbeat. According to this Forbes piece (http://dtn.fm/CbE4N), the hemp-derived cannabidiol (CBD) market is growing at a steady clip, citing statistics by the Hemp Business Journal that show sales of $90 million in 2015 rising to $450 million by 2020. That 38% CAGR will, undoubtedly, be boosted if and when legalization of recreational cannabis becomes a reality in Canada on July 1, 2018. Lexaria is poised to ride that wave to the crest. At present, the company is in negotiations with major cannabinoid companies to license its technology. The smallest deal with any one of these could increase revenues by over $1 million; the largest could increase them by much, much more, as noted by CEO Chris Bunka in a recent interview (http://dtn.fm/mu1ZI). Since Lexaria is employing a lucrative licensing model that is likely to yield 90-100% of revenues as profit, the bottom line won’t be far below the revenue figure. The company expects to have its first major agreement wrapped up by the end of the year.

Presently, Lexaria is the only company in the world that has been awarded a patent for the improved (oral or ingestible, including pills) delivery of all non-psychoactive cannabinoids. Patents have been awarded in the U.S. and Australia and are pending in 40 more countries. This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs. Rather than being a competitor to clinical stage biotech companies, Lexaria is an enabler by offering its molecular delivery technology for licensing.

The results are beginning to show. So far in 2017, revenues have exceeded the total for all of 2016. That trend is likely to continue, since Lexaria’s DehydraTECH technology offers oral digestion of hemp oil in a most delightful way.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is Frontrunner in the Delivery of Non-Psychoactive Cannabinoids

Lexaria Biosciences Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has enhanced the ability of cannabinoid-products companies to deliver active ingredients to the body with its patent-protected technology. This technology is already being applied to the use of non-psychoactive cannabinoids, yielding a high-absorption hemp oil formula that is a source of omega and fatty acids, and patents are pending for tetrahydrocannabinol (THC) and other psychoactive cannabinoids along with nicotine and nonsteroidal anti-inflammatory drugs. An article discussing this reads: “The patent awarded to LXRP for the delivery of all non-psychoactive cannabinoids makes Lexaria the first company in the world to achieve this accomplishment. Awarded in the U.S. and Australia, it is now pending in 44 other countries while supporting research and development on cannabinoids across the industry. The company has filed 19 patent applications in the U.S. and internationally. It also expects additional patent acceptances and issuances in 2017 and over the coming years. In fact, Lexaria has out-licensed the technology as part of its royalty business model, allowing third-party partners and distributors to profit and support their own developments. The numerous deals already signed include those in various state markets, including California, Colorado and Nevada, and a distribution agreement for CBD chewables in Japan and South Korea. Lexaria’s first royalty agreement was with a fast-growing startup, but current negotiations are with larger, more established enterprises. Lexaria is expanding its global reach and expects to continue seeing growth in business deals in broader industry sectors with more well-known consumer brands.”

To view the full article, visit http://dtn.fm/a4OSs

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information about Lexaria, visit www.lexariabioscience.com.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Bioabsorption Tech Boosting Development of CBD Products

October 10, 2017

  • Technology improves absorption of cannabidiol and bioactive compounds into the bloodstream
  • It is now being used on all non-psychoactive cannabinoids and applied to edibles and health food products
  • Patents have been awarded in the U.S. and Australia and are pending in 44 countries

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds. Its patent-protected technology has improved the ability of cannabinoid-products companies to deliver active ingredients to the body. With patents pending for tetrahydrocannabinol and other psychoactive cannabinoids (plus nicotine and non-steroidal anti-inflammatory drugs), the current technology is already being applied to the use of non-psychoactive cannabinoids. This innovation has yielded a high absorption hemp oil formula that is a source of omega and fatty acids.

The health benefits of the technology and the products it has enabled are many. Lexaria has developed a product that can reduce anxiety and stress, increase mental focus and boost physiological performance and recovery. It can reduce pain and inflammation as well, while acting as a vasodilator to improve circulation.

Improved bioabsorption and lowering the cost of edibles are not the only perks of LXRP’s technology. The boost to the product market, and to investors, is already being felt. Avoiding the need for inhalation or co-administering CBD with sugars or sweeteners, the technology accelerates intestinal absorption. This has enabled the development of protein energy bars for sports nutrition and chewable CBD tablets with no sugar. Hemp oil capsules in the TurboCBD™ brand (with American ginseng and Ginkgo biloba) and teas have also been developed.

Lexaria’s technology works by masking the taste of cannabinoids as they’re consumed. It also protects the bioactive ingredients as they pass through the stomach and increases bioabsorption in the intestines by 5–10X. This rate is about equal to that of inhalation, offering a viable alternative to smoking. Onset times are also reduced. Effects may be felt with 15–20 minutes, in contrast to up to two hours via other means.

The patent awarded to LXRP for the delivery of all non-psychoactive cannabinoids makes Lexaria the first company in the world to achieve this accomplishment. Awarded in the U.S. and Australia, it is now pending in 44 other countries while supporting research and development on cannabinoids across the industry. The company has filed 19 patent applications in the U.S. and internationally. It also expects additional patent acceptances and issuances in 2017 and over the coming years.

In fact, Lexaria has out-licensed the technology as part of its royalty business model, allowing third-party partners and distributors to profit and support their own developments. The numerous deals already signed include those in various state markets, including California, Colorado and Nevada, and a distribution agreement for CBD chewables in Japan and South Korea. Lexaria’s first royalty agreement was with a fast-growing startup, but current negotiations are with larger, more established enterprises. Lexaria is expanding its global reach and expects to continue seeing growth in business deals in broader industry sectors with more well-known consumer brands.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Breakthrough Lipid-Based Delivery System Revolutionizes Delivery of Cannabinoids and More

October 3, 2017

Pioneering biotechnology company Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed a breakthrough lipid-based system that facilitates more efficient delivery of bioactive compounds—not only enhancing bio-absorption and bioavailability but also improving taste, smell and the onset of action. Lexaria intends to out-license this patented and proprietary technology, and the company has already applied this delivery technology to its line of products, which includes ViPova, Lexaria Energy and TurboCBD. An article further discussing this reads: “Lexaria’s novel technology, DehydraTECH™, ticks all these boxes by infusing the molecules of organically sourced hemp oil, high in cannabidiol (CBD), inside the molecules of lipids. Lipids seem a natural choice, since the human endocannabinoid system is itself lipid-based. Using them as a vehicle for delivering cannabinoids in curatives results in more absorption, less waste and, just as importantly, fewer side effects (http://dtn.fm/V8blE). With DehydraTECH, a little hemp oil goes a long way, improving the healthful benefits and, of course, saving money.”

To view the full article, visit http://dtn.fm/vMsa5

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information about Lexaria, visit www.lexariabioscience.com.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Tech Discussed at “Cannabis in the Capital Markets” Event

September 29, 2017

  • Clinical studies of TurboCBD™ a topic of discussion at Canadian Securities Exchange-sponsored “Cannabis in the Capital Markets” event
  • Patents cover variety of lipophilic bio-actives, including cannabinoids, nicotine and vitamins
  • Growing portfolio of intellectual property includes 19 patents filed across 44 countries

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), through its proprietary technology for delivering bioactive compounds in lipid formulations, offers licensed partners the ability to include cannabidiol (CBD) in a variety of ingestible products appropriate for medical patients and recreational users alike. In a new report, Grand View Research, Inc., states that the global market for medical cannabis alone is expected to reach a stunning $55.8 billion by 2025 (http://dtn.fm/RfL4n). An increasing interest in the therapeutic value of cannabinoids, especially those delivered in products that can be ingested and not smoked, is one of the main forces driving the market forward, per the report.

Lexaria’s pioneering TurboCBD ™ product presents a revolutionary way to enhance absorption of the benefits CBD provides without having to endure the often unpleasant flavors associated with cannabis compounds. Lexaria’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, with patents pending for THC (tetrahydrocannabinol) and other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and additional molecules.

Dr. Philip Ainsle of the University of British Columbia (UBC) is the principal investigator of Lexaria’s first clinical study of the high-absorption properties of TurboCBD™. The study will evaluate the effects of TurboCBD™ on the cognitive function and cardiovascular health of human volunteers. Dr. Ainsle, co-director of the Centre for Heart, Lung and Vascular Health at the UBC Okanagan Campus in Kelowna, Canada, presented a project update at the Canadian Securities Exchange-sponsored “Cannabis in the Capital Markets” event on September 27 (http://dtn.fm/GV8iN). Lexaria representatives are also scheduled to speak in October at the Southwest Cannabis Conference and Expo in Phoenix, Arizona.

As a business-to-business enterprise, Lexaria’s reach extends to companies located in Canada, several large market states in the U.S., and internationally. An 18-month co-funded research project is underway with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of lipophilic active agents – including those within cannabinoids, vitamins, NSAIDs and nicotine. Results from this study could provide Lexaria with a chemical or physical “fingerprint” that could help to identify Lexaria’s technology at work in consumer products.

Lexaria’s technology is capable of helping companies lower costs while providing the best consumer benefit possible. Several third-party partners have signed deals, letters of intent or memorandums of understanding to utilize Lexaria’s proprietary technology for both THC and CBD products where allowed by law. Lexaria and its partners are targeting markets in Canada, the U.S., Japan, South Korea, Mexico and more. Lexaria’s royalty revenue model includes a range of between five and 10 percent of gross sales.

As a bioscience technology disruptor for edible cannabinoids, Lexaria has several branded CBD products available, including protein energy bars, CBD tablets that contain zero sugar, premium teas and TurboCBD ™ in a high absorption, full spectrum hemp oil capsule. Led by CEO Chris Bunka, Lexaria’s management team includes professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skill sets.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Technology Targets Many Massive Markets

September 25, 2017

  • Technology that improves bio-absorption and bio-availability
  • Bioactive compound delivery system with application across a range of drugs
  • Revenue streams from out-licensing

The word in culinary circles is that where there is fat, there is flavor. That’s because fats (there are several different kinds) have a matchless ability to absorb and preserve flavors. Fats belong to a class of compounds called lipids, which the human digestive system absorbs remarkably efficiently. This characteristic makes them ideal for pairing with hard to digest remedials and tonics. Taking a leaf, perhaps, from haute cuisine, this is exactly what Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is doing. The innovative biotech has developed a lipid-based system that delivers bioactive compounds more efficiently. The patented proprietary technology, which the company plans to out-license, not only augments bio-absorption and bioavailability but also improves taste, smell and onset of action.

Lexaria’s novel technology, DehydraTECH™, ticks all these boxes by infusing the molecules of organically sourced hemp oil, high in cannabidiol (CBD), inside the molecules of lipids. Lipids seem a natural choice, since the human endocannabinoid system is itself lipid-based. Using them as a vehicle for delivering cannabinoids in curatives results in more absorption, less waste and, just as importantly, fewer side effects (http://dtn.fm/F4lzi). With DehydraTECH, a little hemp oil goes a long way, improving the healthful benefits and, of course, saving money.

Lexaria has already applied this innovative delivery technology to its product line, which consists of three distinct brands: ViPova, Lexaria Energy and TurboCBD. ViPova is a delicious Chinese black tea from the province of Yunnan, made from hemp oil-infused within dried evaporated non-fat milk. Introduced in January 2015, the tea is available in a host of varieties and flavors. The Lexaria Energy line is meant for those with busy, active lifestyles. Under this brand, the company has launched a hemp oil-infused protein bar called the Lexaria Energy Bar, which, as its name suggests, provides reserves of energy to boost stamina. In addition, there is Lexaria’s TurboCBD, a brand of technologically enhanced, high absorption hemp oil capsules that came to market in March 2017. TurboCBD’s cannabinoid content is fortified with high-quality American ginseng and ginkgo biloba for support of enhanced focus and memory, along with reduced stress and fatigue.

However, as will be apparent, the DehydraTECH process is not restricted to delivering cannabinoids alone. It can be used to improve the delivery of other cannabinoids (apart from CBD) as well as vitamins, non-steroid anti-inflammatory drugs (NSAIDs) and nicotine. This puts Lexaria in the enviable position of being a natural partner to cannabinoid biotech companies and an enabler rather than a competitor. Moreover, at present, Lexaria is the only company in the world that has been awarded a patent for the improved delivery (oral or ingestible, including pills) of all non-psychoactive cannabinoids. Patents have been awarded in the U.S. and Australia and are pending in 40 more countries. This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs.

Lexaria’s partnership potential is worth taking notice of as landmark M&A deals continue to shape Big Pharma (http://dtn.fm/9PeJL). Its delivery technology has applications in some giant markets. As the referenced article notes, “According to biotech analysis firm EvaluatePharma, the global market for NSAIDs was valued at $11.4 billion in 2014. Meanwhile, the global market for vitamins is on course to reach $9.3 billion by 2020, the market for alternative nicotine delivery technologies is at an all-time high following recent FDA proposals, and consumer sales of cannabinoids are expected to reach $2.1 billion by 2020. All told, the market potential for Lexaria’s flagship platform could be huge.”

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – University of British Columbia to Conduct Clinical Study of Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Game-Changing Oral CBD Product

September 15, 2017

While cannabidiol and other marijuana-derived substances are traditionally smoked, this can cause damage to the lungs, and edible cannabis products have their drawbacks, too—typically being filled with sugars or other sweeteners to mask the unpleasant flavor associated with cannabis compounds. With its pioneering TurboCBD™ product, however, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral CBD intake, having engineered the product to enhance absorption through the intestinal tract without active compounds being destroyed by stomach acid or broken down by the liver, and this revolutionary product also masks the unpleasant flavor of cannabis compounds. An article further discussing this topic reads: “In August 2017, the University of British Columbia (UBC) announced (http://dtn.fm/5NgxC) that it will conduct the first clinical study of the high-absorption product while evaluating its effects on cognitive function and cardiovascular health of human volunteers. Currently, Lexaria is the only company to have been awarded a patent for delivery of ingestible non-psychoactive cannabinoids. It holds patents in the U.S. and Australia, and more are pending in over 40 other countries. The upcoming UBC study will be double-blind and placebo controlled. Researchers will measure the effects after a single dose and after seven days of daily doses. The 24 volunteers will consist of young and old individuals, whose glucose, blood pressure, vascular function, cognition, and physical performance will be measured. Blood samples, exercise tests, heart rate, respiration, and neuropsychological tests, among other measurements, will be conducted as well. These tests will provide a complete set of pharmacokinetic and pharmacodynamic performance data of Lexaria’s TurboCBD™.”

To view the full article, visit http://dtn.fm/MdTg7

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaBioscience.com

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral CBD Product to Be Tested by the University of British Columbia

September 13, 2017

  • The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product
  • TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x
  • The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of administration

Traditionally, cannabidiol (CBD) is ingested via inhalation, which can harm the lungs, and many edible products contain unwanted sugars or sweeteners. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product. Engineered to increase absorption through the intestinal tract, without active compounds destroyed by stomach acid or broken down by the liver, the product also masks the flavor of compounds with undesirable tastes. In August 2017, the University of British Columbia (UBC) announced (http://dtn.fm/f8UPH) that it will conduct the first clinical study of the high-absorption product while evaluating its effects on cognitive function and cardiovascular health of human volunteers.

Currently, Lexaria is the only company to have been awarded a patent for delivery of ingestible non-psychoactive cannabinoids. It holds patents in the U.S. and Australia, and more are pending in over 40 other countries. The upcoming UBC study will be double-blind and placebo controlled. Researchers will measure the effects after a single dose and after seven days of daily doses. The 24 volunteers will consist of young and old individuals, whose glucose, blood pressure, vascular function, cognition, and physical performance will be measured. Blood samples, exercise tests, heart rate, respiration, and neuropsychological tests, among other measurements, will be conducted as well. These tests will provide a complete set of pharmacokinetic and pharmacodynamic performance data of Lexaria’s TurboCBD™.

Regarding the expected outcome of the study, professor Philip Ainslie, PhD, stated in the recent report, “…To quantify the pharmacokinetics of TurboCBD™ will allow us to make informed recommendations of optimum dosing in order to improve vascular health and performance throughout healthy aging. Once we understand these processes better, the applications to various clinical populations can then be explored…

Details of the test results are expected to be released once the study is completed and the data are interpreted.

According to Lexaria, its “plant-to-bloodstream” product amplifies intestinal absorption by 5-10x. It uses fatty acids, which combine with the active pharmaceutical ingredient to block them from bitter taste receptors on the tongue. Active ingredients are protected by lipids as they pass through the stomach. In the small intestine, long chain fatty acids are absorbed directly into the lymphatic system, while medium chain fatty acids are absorbed via the liver.

An August 2015 in vitro absorption study, conducted in a third party lab, found a 499 percent increase in CBD bioabsorption in the intestines. A human focus study in March 2016 revealed the onset of THC effects in 15 to 20 minutes, while test subjects praised the taste of the product. The company also entered into a collaborative research agreement with Canada’s National Research Council, which was signed in February 2017.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues Showcasing Proprietary Research at Cannabis Investment Conferences

September 7, 2017

  • Proprietary Lexaria technology improves delivery of bioactive compounds in a variety of products, including cannabis-based gourmet foods
  • Market predictions for the legal marijuana industry forecast $50 billion in sales by 2026
  • 19 patent applications filed and pending in more than 40 countries

Following a successful showing at the inaugural Institutional Capital & Cannabis Conference (IC3) in California earlier this month, Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka expects the company to be noticed by investors. Bunka’s presentation of the company’s latest technology slated to benefit the cannabis industry includes the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s TurboCBD™ product.

The study, which aims to evaluate the effects of TurboCBD™ on both cardiovascular health and cognitive function, will have a double-blind and placebo controlled cross-over design measuring effects after a single dose, as well as seven days of daily dosing, in 24 volunteers (http://dtn.fm/2LsAq).

“Results will advance Lexaria’s ability to custom design products that increase the leading performance our technology already offers to customers,” Bunka said in a press release outlining the project.

While Hurricane Irma has postponed Bunka’s next mainstream presentation, slated for the now on-hold Institutional Capital & Cannabis Conference in Miami Beach, Florida, Lexaria continues its drive to showcase the benefits of the company’s unique patented delivery technology (http://dtn.fm/7dVat).

Lexaria researchers work to solve a critical problem facing the cannabis industry – the fact that most of the CBD and tetrahydrocannabinol (THC) that people consume, through any method, is literally flushed away in the proverbial toilet. To that end, Lexaria has focused on discovering new technologies that can more efficiently deliver cannabinoids to the bloodstream, where they can have their desired effect.

Lexaria’s patented DehydraTECH™ technology solves this problem by delivering cannabinoids in an oral form that masks any undesirable taste but increases bioabsorption, speed of effectiveness and potency. This method of delivery is a more viable and healthier method than smoking or vaping cannabis, a route that non-users and medical providers frown upon due to documented health concerns.

Marijuana is now legal in some form in 29 states and Canada. In fact, the Canadian government is expected to legalize adult use of cannabis in 2018, and there are growing movements in the U.S. to legalize cannabis nationwide, as well. Industry experts predict that U.S. retail sales alone could reach $50 billion by 2026 (http://dtn.fm/9elrN).

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Begins Laboratory Venture with National Research Council

August 31, 2017

  • Collaborative venture could lead to strengthening of company’s patent portfolio, new commercial opportunities
  • Firm receives patent in Australia, anticipates entering that market through cannabinoid licensing arrangements and product distribution partnerships
  • LXRP names Allan Spissinger acting chief financial officer

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has begun laboratory work with the National Research Council (“NRC”) (http://dtn.fm/e4oZB). The collaboration will begin studies using LXRP’s patented technologies. The research will include the company’s technology in vitamins, NSAIDs, nicotine and cannabinoids utilizing lipophilic active agents. LXRP has patented technology involving how those agents are ingested into the human body in various edibles, such as beverages, foods, capsules and others means.

LXRP has also named Allan Spissinger (http://dtn.fm/ziT65) as its acting chief financial officer, secretary and treasurer. He has been with the company since September 2014, when he joined as corporate controller. A CPA, he has more than 10 years’ experience in corporate IT infrastructure and software development before focusing of finance and accounting.

The firm, based in Kelowna, British Columbia, Canada, is a food biosciences company which is a technology disrupter for edible CBDs. It markets a high absorption hemp oil formulation for exotic teas, protein energy bars and high absorption hemp oil capsules that aid in the body’s absorption of CBDs. It is focusing on developing more products for the edible cannabis market.

The joint research venture with the NRC will use advanced analytical techniques. Practical application of the resulting research could broaden or strengthen LXRP’s intellectual property portfolio and even lead to additional commercial arrangements, per a recent statement from the company.

LXRP has a number of international patents, including the recent 20-year effective patent approval issued by Australia (http://dtn.fm/D3NMa) for the company’s edible cannabis absorption method, time of onset and taste of cannabinoid’s active agents in food.

“We are very pleased to have received this patent which effectively covers all cannabis oil extract formulated edibles using our technology in Australia,” Chris Bunka, chief executive officer of LXRP, stated in a news release. “This patent award allows us to confidently enter the recently legalized Australian cannabis marketplace where we will seek additional licensing and product distribution partnering opportunities.”

A similar patent was granted in the U.S. in 2016, and Bunka added that LXRP anticipates progress on its patent portfolios throughout the remainder of 2017 and into 2018. In the U.S., the company successfully filed a provisional patent application (http://dtn.fm/0kNSJ) and stock and option awards in June 2017. It expands the company’s existing patent in the U.S. to microwave processing.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Clinical Study of High Absorption TurboCBD™ Product

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s TurboCBD™ product. The study, which aims to evaluate the effects of TurboCBD™ on both cardiovascular health and cognitive function, will have a double-blind and placebo controlled cross-over design measuring effects after a single dose, as well as seven days of daily dosing, in 24 volunteers. “Lexaria is proud to be advancing our collective knowledge of the benefits of CBD specifically showcasing the benefits of Lexaria’s unique patented delivery technology,” Chris Bunka, CEO of Lexaria, stated in the news release. “Results will advance Lexaria’s ability to custom design products that increase the leading performance our technology already offers to customers.”

To view the full press release, visit http://dtn.fm/3vZKM5

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaBioscience.com

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Scheduled to Attend Two Cannabis Conferences in September

August 29, 2017

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced its plans to attend two cannabis investment conferences in September. The first, the Investorshub International Cannabis Conference, will be held at the JW Marriott in downtown Los Angeles on September 1-2. The second, the Institutional Capital & Cannabis Conference (East), is scheduled to take place on September 7-8 in Miami Beach. This morning’s news release also included an update on the company’s financing activities. Notably, Lexaria has received and executed a notice of conversion related to certain convertible debt, extinguishing a $45,000 convertible debt plus interest in exchange for 307,500 restricted common shares at the contracted conversion price of $0.15. The company also issued 32,433 common shares, at a conversion price of $0.37, to a director in order to settle $12,000 of debt.

To view the full press release, visit http://dtn.fm/RiU8X

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaBioscience.com

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Disruptive Process Pioneered by Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Creates Superior Cannabis Edibles

August 25, 2017

Common complaints among consumers of cannabis edibles include the presence an unpleasant taste, but this and other inadequacies are being overcome through the innovations of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP). Lexaria’s disruptive process masks the unpleasant taste of cannabis, and the company’s lipophilic enhancement technology also changes the way cannabinoids enter the body while significantly speeding up the timeframe in which THC’s effects are felt and increasing bio-absorption by as much as tenfold. As noted in a recent NNW article:

“Because cannabinoids are absorbed poorly by the gastrointestinal tract, many cannabis users turn to other administration routes, like smoking, for greater effectiveness. Lexaria’s proprietary technology for better delivery of bioactive compounds solves the problem of poor absorption, increasing the bio-absorption of cannabis edibles by between five and tenfold. The effects of the THC from an edible product created using Lexaria’s patented process are also felt much more quickly—taking effect within 15-20 minutes as opposed to one to two hours. The possibilities enabled by Lexaria’s technology are multifold and exciting. For instance, excessive amounts of sugar have previously had to be included in cannabis edibles to mask the unwanted taste, but because Lexaria’s technology eliminates that undesirable flavor, zero-sugar formats are now possible for cannabinoid edibles.”

To view the full article, visit http://dtn.fm/Ffb9W

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.lexariabioscience.com.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Revolutionary Process Creates Superior Cannabinoid Edibles

  • 19 patent applications filed in the United States and internationally (under the Patent Cooperation Treaty), with national filings in 44 countries
  • Collaborative research and development agreement with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of certain compounds, including those in cannabinoids, vitamins, NSAIDs and nicotine
  • Out-licenses its patented technology to third party partners, with several deals signed or pending

When Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) researchers tackled the issue facing consumers of edible cannabinoids – poor absorption of the product’s bioactive compounds by the body’s gastrointestinal tract – an important statement led the way: bioavailability matters. The company realized that if hemp oil ingredients were infused within lipids found in popular foods, the common problems of bad taste, poor absorption in the body and lack of product variety could be solved.

Lexaria has since developed a superior method of lipid-delivery technology through a patented process that does this by infusing the beneficial elements of hemp oil to lipid molecules. Lexaria reminds consumers that it is not mixing hemp oil into a product; it is infusing organically sourced, high purity hemp oil inside the molecules of other ingredients to produce superior tasting and performing food and beverages, including premium teas, protein energy bars and hemp oil capsules formulated with ginseng and ginkgo for enhanced memory and focus.

Additionally, this technologically superior method of delivery is being considered for other products in demand by consumers, namely nicotine-based products. Lexaria’s method could remove many of the dangerous side effects of nicotine, although the patented molecular delivery technology for this product remains in its early stages (http://dtn.fm/c2VCP).

Lexaria is also seeking patents to use its lipophilic enhancement technology for tetrahydrocannabinol (THC) and other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs such as ibuprofen), nicotine and other molecules. New business-to-business relationships are on the horizon in the fields of vitamins, NSAIDs and nicotine delivery.

For more information, visit the company’s website www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Revolutionary Process Creates Superior Cannabinoid Edibles

August 17, 2017

  • Disruptive, patented technology is set to revolutionize the edible cannabis market
  • Company has patent applications in 45 countries, including 18 applications in the U.S.
  • Technology is patent-protected for CBD and all other non-psychoactive cannabinoids, with patents pending for THC, other psychoactive cannabinoids, NSAIDs, nicotine and other molecules

A common complaint among the consumers of cannabis edibles is an unpleasant taste that can often be detected, but that unpleasant taste and other inadequacies of cannabis edibles are being overcome thanks to the incredible innovations of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP).

Lexaria is literally bringing new flavor to the marijuana industry with its disruptive process, which masks the unpleasant taste associated with cannabis. Lexaria’s lipophilic enhancement technology also changes the way cannabinoids enter the body; substantially speeds up the time frame in which tetrahydrocannabinol (THC) effects can be felt after consuming a cannabinoid edible; and increases bio-absorption by up to 10 times, making the absorption from cannabis edibles equal to the absorption from inhaled cannabis.

Because cannabinoids are absorbed poorly by the gastrointestinal tract, many cannabis users turn to other administration routes, like smoking, for greater effectiveness. Lexaria’s proprietary technology for better delivery of bioactive compounds solves the problem of poor absorption, increasing the bio-absorption of cannabis edibles by between five and tenfold. The effects of the THC from an edible product created using Lexaria’s patented process are also felt much more quickly—taking effect within 15-20 minutes as opposed to one to two hours.

The possibilities enabled by Lexaria’s technology are multifold and exciting. For instance, excessive amounts of sugar have previously had to be included in cannabis edibles to mask the unwanted taste, but because Lexaria’s technology eliminates that undesirable flavor, zero-sugar formats are now possible for cannabinoid edibles.

Lexaria’s process involves taking the healthy cocktail of molecules found in the company’s organically sourced hemp and infusing those molecules inside the molecules of other ingredients. Lexaria works with lipids, because the endocannabinoid system in the human body is lipid-based. The company has found its method to be a more efficient means of delivering hemp oil ingredients to the body, making a small amount of hemp seed oil inside a Lexaria product equal to a great deal of hemp oil delivered via a product that wasn’t created using the company’s revolutionary technology.

Lexaria’s pioneering technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids. Patents are further pending for THC and other psychoactive cannabinoids, along with nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. In the United States, 18 patent applications have been filed, and international and national patent filings have been made in 44 other countries.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Regulation Forcing Drug and Cigarette Companies to Be More Responsible is Great News for Lexaria (LXRP), says CEO

August 14, 2017

In an interview with Stock Day, CEO Chris Bunka of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) discussed the company’s recent achievements and its plans for the near future. Revenues are climbing, exceeding, so far in 2017, the total for all of 2016, and the potential for further increases is imminent. The company is in negotiation with at least four large pharmaceutical companies to license its technology. The smallest of these could increase revenues by $1 million; the largest could increase revenues by much, much more, according to Bunka. Getting any of these deals signed will boost the bottom line almost as much as they would raise revenues. Lexaria will be employing a lucrative licensing model that is likely to yield 90-100% of revenues as profit. The company expects to have its first major agreement wrapped up by the end of the year.

Apart from attracting the attention of big pharma, Lexaria has been working with the National Research Council (NRC) of Canada, an agency of the Canadian federal government, to explore the effects of its technology. The company has developed technology that allows non-psychoactive cannabinoids, vitamins, non-steroid anti-inflammatory drugs (NSAIDs) and nicotine to be absorbed at much higher rates. Lexaria’s superior delivery system offers the promise of potentially reducing required doses of these substances, since less of them goes to waste. The technology also speeds up delivery. It can deliver payload molecules to the bloodstream in 15-25 minutes, as opposed to 60-90 minutes for current methods, and is already in use in a number of consumer products.

Lexaria recently raised $4 million in capital. The company intends to spend part of the proceeds in setting up an R&D program for nicotine. The initiative comes at an opportune time. In August, the FDA announced “a new comprehensive plan for tobacco and nicotine regulation that will serve as a multi-year roadmap to better protect kids and significantly reduce tobacco-related disease and death” (http://dtn.fm/hlb4O). The agency plans to stimulate public dialogue on lowering nicotine levels in combustible cigarettes to non-addictive levels. This is good news for Lexaria, which is hoping its technology can provide a delivery method for nicotine that is safer than smoking. As its CEO has remarked, “Regulation is great news for Lexaria.”

The interview can be heard at http://dtn.fm/194Mx

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Discusses Company’s Progress in Interview

August 10, 2017

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced that its chief executive officer, Chris Bunka, was featured in a recent interview on the Uptick Network Stock Day Radio Show. Bunka leveraged the platform to discuss Lexaria’s overall accomplishments in the past three months, as well as the company’s expectations for profitability moving forward. He notes that ongoing research and development programs could open both the NSAID and Nicotine markets to Lexaria, providing an opportunity to significantly increase corporate revenues and facilitate further expansion. “In the next 12 months you won’t even recognize Lexaria,” Bunka states in the interview. “If you look at it today and look at where we are going to be in the next 12 months… I think we are going to be an entirely different company.” The full interview is available for review at http://dtn.fm/X5d1k.

To view the full press release, visit http://dtn.fm/B8tKZ

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria

Lexaria Bioscience Corp. is a biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been proven to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit http://www.LexariaEnergy.com

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Search

    Categories

    Select A Category
  • 21st Century Holding Company TCHC (1)
  • 5BARz International Inc. BARZ (12)
  • 5G Wireless Communications Inc. FGWC (8)
  • 92 Resources Corp. RGDCF (12)
  • A.P. Pharma Inc. APPA (3)
  • Abazias Inc. ABZA (2)
  • ABcann Global Corp. ABCCF (18)
  • ABV Gold ABVG (11)
  • ACME Sports & Entertainment Inc. ASEN (2)
  • Adaptive Medias Inc. ADTM (6)
  • Advanced ID Corp. AIDO (5)
  • Advanced Medical Isotope Corp. ADMD (10)
  • Advanced Resources Group Ltd. AVRG (3)
  • Advanced Viral Research Corp. ADVR (9)
  • Advanced Visual Systems Inc. AVSC (10)
  • Advanced Voice Recognition Systems Inc. AVOI (11)
  • Advanced Wound Technologies Inc. AWTM (4)
  • Advaxis Inc. ADXS (2)
  • Agora Holdings Inc. AGHI (33)
  • Ahead of the Bulls (1)
  • AISystems, Inc. ASYI (11)
  • Aladdin Trading & Company ADTD (29)
  • Algae Dynamics Corp. ADYNF (31)
  • All American Gold Corp AAGC (13)
  • All Asia Licensing Inc. AASI (1)
  • ALL Fuels & Energy Company AFSE (49)
  • All Grade Mining Inc. HYII (3)
  • All Penny Stocks (3)
  • Allarae Healthcare Inc. ALHI (5)
  • Alliance Creative Group ACGX) (15)
  • Alliance Recovery Corp. ARVY (34)
  • Alltemp, Inc. LTMP (1)
  • AlphaTrade.com APTD (2)
  • Alpine TLI Group Inc. APGR (7)
  • ALR Technologies Inc. ALRT (9)
  • Alternative Construction Technologies Inc. ACCY (10)
  • Alternative Energy Development Corp. ADEC (1)
  • Alternative Fuel Technology Inc. AFTC (1)
  • Alternet Systems Inc. ALYI (47)
  • AM Oil Resources & Technology Inc. AMOR (8)
  • Amarin Corp. AMRN (2)
  • Amaru Inc. AMRU (2)
  • Amerex Group, Inc AEXG (16)
  • American Capital Partners Inc. APRJ (1)
  • American Fiber Green Products Inc. AFBG (1)
  • American Oriental Bioengineering Inc. AOB (3)
  • American Racing Capital Inc. AMRA (2)
  • American Software (2)
  • Amgen Inc. AMGN (2)
  • AmMex Gold Mining Corp. AMXG (2)
  • Ampex Corp AMPX (1)
  • Andover Medical Inc. ADOV (2)
  • Angstrom Microsystems Inc. AGMS (46)
  • Apolo Gold and Energy Inc. APLL (1)
  • Apple Inc. AAPL (13)
  • AppSwarm, Inc. SWRM (22)
  • Aquasil International Inc. AQUS (3)
  • Armco Metals Holdings Inc. AMCO (36)
  • AspenBio Pharma APPY (1)
  • Assured Pharmacy Inc. APHY (1)
  • Asta Funding Inc. ASFI (2)
  • Atlantic Energy Solutions Inc. AESO (1)
  • ATSI Communications Inc. ATSX (1)
  • Augme Technologies Inc. AUGT (70)
  • Auric Mining Corp. AUMY (3)
  • Automated Vending Technologies Inc. AVTC (3)
  • Automotive Company GNAU (11)
  • AV1 Group, Inc. AVOP (3)
  • Avalon Oil and Gas Inc. AOGN (16)
  • Avant Diagnostics Inc. AVDX (29)
  • Avatar Systems Inc. AVSY (3)
  • Axiom Management Inc. AXMA (3)
  • Axis Technologies Inc. AXTG (2)
  • B2Digital Inc. BTOD (18)
  • Balatia Airlines BLTA (2)
  • Bald Eagle Energy Inc. BEEI (18)
  • Banjo & Matilda Inc. BANJ (8)
  • Barchart.com (4)
  • Beacon Enterprise Solutions Group BEAC (47)
  • Beacon Equity Research (552)
  • Beijing Med-Pharm Corp. BGJP (2)
  • Bergamo Acquisition Corp. BGMO (15)
  • Big Tree Group Inc. BIGG (36)
  • Bio-Clean International Inc. BCLE (1)
  • Bio-Matrix Scientific Group Inc. BMSN (1)
  • BioCentric Energy Holdings Inc. BEHL (1)
  • Biomagnetics Diagnostics Corp. BMGP (3)
  • bioMETRX Inc. BMRX (1)
  • Bionic Products Corp. BNPD (4)
  • Biophan Technologies Inc. BIPH (1)
  • BioSolar Inc. BSRC (22)
  • Biotech Holdings Ltd. BIOHF (3)
  • BizRocket.com Inc. BZRT (9)
  • Black Diamond Brands Corp. BDMHF (1)
  • Blue Diamond Ventures Inc. BLDV (1)
  • Blue Moon Zinc Corp. BMOOF (7)
  • Blue Water Global Group Inc. BLUU (7)
  • Blugrass Energy Inc. BLUG (4)
  • Bollente Companies, Inc. BOLC (7)
  • BoonMarket.com (1)
  • Boreal Water Collection Inc. BRWC (23)
  • Boston Therapeutics Inc. BTHE (20)
  • Bridgetech Holdings International Inc. BGTH (1)
  • Brighton Oil & Gas Inc. BROG (8)
  • Britannia Mining Inc. BMIN (14)
  • Brite Strike Tactical Illumination Products, Inc. BSTI (41)
  • Brookside Technology Holdings Corp BKSD (2)
  • Bullzi Security Inc. BLLZ (3)
  • BWI Holdings Inc. BWIH (165)
  • Cache Elite Inc. ILUS (9)
  • Cal-Bay International Inc. CBYI (6)
  • Callisto Pharmaceuticals, Inc. (1)
  • Calpian Inc. CLPI (27)
  • CAMAC Energy Inc. CAK (2)
  • Canam Energy Inc. CNGJ (10)
  • CanAm Uranium Corp. CAUI (58)
  • Cannabics Pharmaceuticals Inc. CNBX (14)
  • Capital City Energy Group Inc. CETG (18)
  • Car Monkeys Group CKMY (15)
  • Carbon Sciences Inc. CABN (21)
  • CardioVascular BioTherapeutics Inc. CVBT (5)
  • Cardium Therapeutics Inc. CXM (44)
  • Cascade Technologies Inc. CSDT (2)
  • Cascadia Investment Inc. CDIN (4)
  • Casey Corp. CCPR (1)
  • Cashcow Magazine (4)
  • Cavico Corp. CVIC (3)
  • CD International Enterprises, Inc. CDII (48)
  • CDC Corp. CHINA (4)
  • CelebDirect Inc. CELI (3)
  • Cellceutix Corp. CTIX (18)
  • CellCyte Genetics Corp. CCYG (3)
  • Century Group, Inc. CEYG (1)
  • CEOcast (184)
  • CepTor Corp. CEPO (1)
  • Cereplast Inc. CERP (9)
  • Chancery Resources Inc. CCRY (3)
  • Changing Times Vitamins Inc. SGTB (12)
  • CHDT Corp. CHDO (5)
  • Cherubim Interests Inc. CHIT (36)
  • China 3C Group CHCG (13)
  • China America Holdings Inc. CAAH (8)
  • China Direct Inc. CDS (4)
  • China Education Alliance Inc. CEUA (4)
  • China Energy Recovery Inc. CGYV (12)
  • China Growth Development Inc. CGDI (2)
  • China Health Management Corp CNHC (7)
  • China Health Resource Inc. CHRI (14)
  • China INSOnline Corp. CHIO (1)
  • China Jiangsu Golden Horse Steel Ball Inc. CJGH (3)
  • China Logistics Group Inc. CHLO (11)
  • China Media Group Corp. CHMD (2)
  • China Medicine Corporation CHME (5)
  • China Nuvo Solar Energy Inc. CNUV (3)
  • China Organic Agriculture Inc. CNOA (11)
  • China Petroleum and Chemical Corp. SNP (2)
  • China Voice Holding Corp. CHVC (47)
  • China Wind Systems Inc. CWSI (6)
  • China Wireless Communications Inc. CWLC (4)
  • China Yongxin Pharmaceuticals Inc. CYXN (5)
  • China YouTV Corp. CYTV (1)
  • ChinaTel Group Inc. CHTL (1)
  • Chineseinvestors.com, Inc. CIIX (74)
  • ChromaDex Corp. CDXC (3)
  • City Capital Corp. CTCC (2)
  • Cityside Tickets CIST (21)
  • CleanTech BioFuels Inc. CLTH (10)
  • Cleantech Transit Inc. CLNO (3)
  • Clearly Canadian Beverage Corp. CCBEF (13)
  • Cleartronic Inc. CLRI (52)
  • Clenergen Corp. CRGE (37)
  • CMG Holdings Inc. CMGO (2)
  • Coastal Integrated Services Inc. COLV (13)
  • Coil Tubing Technology Inc. CTBG (1)
  • Colorado Goldfields Inc. CGFI (5)
  • Colt Resources Inc. COLTF (13)
  • Columbia River Resources Inc. CRVR (1)
  • CoMedia Corp. CMTN (1)
  • CommercePlanet Inc. CPNE (4)
  • Compress Technologies Inc. CTLG (17)
  • Conforce International Inc. CFRI (2)
  • Connect-A-Jet.com CAJT (9)
  • Cono Italiano Inc. CNOZ (12)
  • Consorteum Holdings, Inc. CSRH (160)
  • ContentChecked Holdings Inc. CNCK (60)
  • Continental Fuels Inc. CFUL (2)
  • Converde Energy USA Inc. XFUL (12)
  • Convergence Technology Group Inc. CNVC (7)
  • Copper King Mining Corp. CPRK (2)
  • Cord Blood America Inc. CBAI (102)
  • Crdentia Corp CRDT (12)
  • Creative Vistas Inc. CVAS (2)
  • Crystal International Travel Group Inc. CINT (4)
  • Cubic Energy Inc. QBC (2)
  • Cybermesh International Corp. CYTL (1)
  • Cyclone Power Technologies Inc. CYPW (9)
  • CYIOS Corp. CYIO (1)
  • Daily Views (13)
  • Dakshidin Corp. DKSC (5)
  • Data Call Technologies Inc. DCLT (25)
  • Daulton Capital Corp. DUCP (26)
  • Davi Skin Inc. DAVN (1)
  • Debt Resolve Inc. DRV (2)
  • Debut Broadcasting Corporation Inc. DBTB (1)
  • Deep Blue Marine Inc. DPBM (6)
  • Deep Down Inc. DPDW (15)
  • Deer Valley Corp. DVLY (2)
  • Defense Solutions Inc. DFSH (3)
  • Delta Mining and Exploration Corp. DMXC (1)
  • Dermisonics Inc. DMSI (1)
  • Destination Television Inc. DSTV (17)
  • Dhanoa Minerals Ltd. DHNA (4)
  • DigitalPost Interactive Inc. DGLP (8)
  • Document Capture Technologies Inc. DCMT (3)
  • DoMark International Inc. DOMK (29)
  • Dominovas Energy Corp. DNRG (73)
  • Dragon Capital Group Corp. DRGV (11)
  • Dragon International Group Corp. DRGG (2)
  • Duma Energy Corp. DUMA (20)
  • Duska Therapeutics Inc. DSKA (1)
  • Dutton Associates (88)
  • DXP Enterprises Inc. DXPE (4)
  • Dynamic Media Holdings Inc. DYMH (6)
  • Dynamic Response Group Inc. DRGP (6)
  • Dynasty Limousine Inc. DNYS (19)
  • Earth Dragon Resources Inc. EARH (10)
  • Eastbridge Investment Group Corp. EBIG (1)
  • Ebenefits Direct, Inc. EBFD (21)
  • eCareer Holdings Inc. ECHI (9)
  • Echo Therapeutics Inc. ECTE (5)
  • EcoloCap Solutions Inc. ECOS (2)
  • Ecologic Transportation Inc. EGCT (11)
  • Ecosciences Inc. ECEZ (1)
  • Ecotality, Inc. ECTY (67)
  • eCrypt Technologies Inc. ECRY (79)
  • EdgeTech International Inc. EGIL (6)
  • eDoorways Corp. EDWY (183)
  • EFoodSafety.com Inc. EFSF (4)
  • EFuel EFN Corp. EFUL (1)
  • EGPI Firecreek Inc. EFIR (1)
  • Elephant Talk Communications Corp. ETAK (8)
  • Elephant Talk Communications Inc. ETAK (2)
  • Elleipsis Global Travel Solutions Inc. EGTS (3)
  • Elray Resources Inc. ELRA (11)
  • Elron Electronic Industries Ltd. ELRN (1)
  • Emerging Media Holdings Inc. EMDH (22)
  • Empire Energy Corporation International EEGC (3)
  • Endeavor Explorations Inc. EAVR (7)
  • Endeavour Silver Corp. EXK (3)
  • Endevco Inc. EDVC (2)
  • Energtek Inc. EGTK (61)
  • Enherent Corp. ENHT (2)
  • EnterConnect Inc. ECNI (5)
  • Enterprise Oilfield Group Inc. E.TO (13)
  • EnXnet Inc. EXNT (1)
  • Epazz, Inc. EPAZ (28)
  • Equity Stock Analysis (1)
  • ER Urgent Care Holdings Inc. ERUC (6)
  • ERF Wireless Inc. ERFB (15)
  • Essential Innovations Technology Corp. ESIV (2)
  • Etelcharge.com Inc. ETLC (3)
  • Ethema Health Corporation GRST (7)
  • Euoko Group Inc. EUOK (2)
  • EV Innovations Inc. EVII (189)
  • EV Transportation Inc. EVTP (7)
  • EVIO, Inc. EVIO (9)
  • Exchange Media Corp. EXMD (9)
  • Exeter Resource Corp. XRA (2)
  • eXp World Holdings, Inc. EXPI (81)
  • Expert Group Inc. EXPT (5)
  • ExpressIR Inc. (1)
  • Extreme Motorsports of California, Inc. EMOC (26)
  • ezBanc-A Stocklender's Journal (6)
  • Falcon Crest Energy FCEN (75)
  • Falcon Ridge Development Inc. FCNR (2)
  • Famous Uncle Als Hot Dogs & Grille Inc FDOG (10)
  • Fastfunds Financial Corp. FFFC (17)
  • Financial Media Group, Inc. FNGP (26)
  • Financial Services Exchange FSE (1)
  • First Cobalt Corp. FTSSF (5)
  • First Titan Corp. FTTN (45)
  • FlexWeek Inc. FXWK (11)
  • FluoroPharma Medical Inc. FPMI (46)
  • Foldera, Inc. FDRA (11)
  • Force Energy Corp. FORC (5)
  • FormCap Corp. FRMC (29)
  • Fortune Market Media Inc. FTMM (5)
  • Franklin Mining Inc. FMNJ (1)
  • Freedom Leaf Inc. FRLF (12)
  • Fresh Harvest Products Inc. FRHV (7)
  • Fresh Promise Foods Inc. FPFI (12)
  • Freshstart Properties Inc. FSPP (1)
  • FrogAds Inc. FROG (6)
  • Frozen Food Gift Group Inc. FROZ (5)
  • Fund.com, Inc. FNDM (56)
  • Fushi Copperweld Inc. FSIN (2)
  • GainClients Inc. GCLT (9)
  • Galenfeha Inc. GLFH (28)
  • Gastar Exploration Ltd. GST (2)
  • Gemini Explorations Inc. GXPI (12)
  • Gen2media Corp. GTWO (2)
  • General Environmental Management Inc. GEVI (56)
  • General Metals Inc. GNMT (1)
  • General Steel Holdings Inc. GSI (3)
  • GeoBio Energy Inc. GBOE (1)
  • GeoEye Inc. GEOY (4)
  • GeoPharma Inc GORX (1)
  • Giggles N’ Hugs Inc. GIGL (90)
  • Global Alumina Corp. GLA.U (1)
  • Global General Technologies Inc. GLGT (1)
  • Global Payout Inc. GOHE (64)
  • Global Realty Development Corp. GRLY (10)
  • Global Resource Corporation GBRC (48)
  • Global Roaming Distribution Inc. GRDB (34)
  • GlobalWise Investments Inc. GWIV (129)
  • GNCC Capital Inc. GNCP (24)
  • Golden West Brewing Company Inc. GWBC (3)
  • GoldSpring Inc. GSPG (4)
  • Google, Inc. GOOG (8)
  • GotStocks.net (1)
  • Grandview Gold Inc. GVGDF (2)
  • Gray Publishing & Media, Inc. GPMIJ (15)
  • Graystone Park Enterprises Inc. GPKE (7)
  • Great Plains Holdings Inc. GTPH (28)
  • Green Earth Technologies GETG (1)
  • Green Star Alternative Energy Inc. GSAE (2)
  • Green Star Products Inc. GSPI (2)
  • Green Technology Solutions Inc. (GTSO) (19)
  • Greenbelt Resources Corp. GRCO (1)
  • Greenchek Technology Inc. GCHK (18)
  • Greenkraft, Inc. GKIT (13)
  • Greenstone Holdings Inc. GSHN (2)
  • GREM USA GRMU (2)
  • Grey Cloak Tech, Inc. GRCK (14)
  • GRILLiT Inc. GRLT (8)
  • Growblox Sciences Inc. GBLX (24)
  • GT Legend Automotive Holdings Inc. GTLA (2)
  • GTX Corp GTXO (49)
  • Gulf Western Petroleum Corp. GWPC (3)
  • GWS Technologies Inc. GWSC (4)
  • Halcyon Jets Holdings Inc. HJHO (15)
  • Halitron Inc. HAON (11)
  • Hanover Financial Services (17)
  • Harbin Electric Inc. HRBN (2)
  • Harvey Electronics Inc. HRVE (1)
  • Hasco Medical Inc. HASC (7)
  • Hathway Corp. HWYI (1)
  • HeadsUp Entertainment International Inc. HDUP (3)
  • Healthnostics Inc. HNSO (1)
  • HealthSonix Inc. HSXI (1)
  • HealthSport Inc. HSPO (14)
  • Heartland Inc. HTLG (1)
  • Heartland Oil and Gas Corp. HTOG (7)
  • Hemis Corporation HMSO (19)
  • Hemisphere Gold Inc. HPGI (1)
  • Hemp Inc. HEMP (25)
  • Hendrx Corp. HDRX (1)
  • Hi-Shear Technology Corp. HSR (3)
  • HighCom Global Security Inc. HCGS (17)
  • HII Technologies Inc. HIIT (8)
  • Holloman Energy Corp. HENC (2)
  • Holmes Osborne (6)
  • Hologic Inc. HOLX (4)
  • Home Shopping Latino Inc. HSPG (8)
  • Hong Kong Highpower Technology Inc. HPJ (2)
  • HotOTC (61)
  • HotStockChat (3)
  • HotStockMarket (HSM) (3)
  • HST Global Inc. HSTC (11)
  • Hunt Gold Corp. HGLC (32)
  • HWI Global Inc. HWIC (3)
  • Hydrogen Corp. HYDG (1)
  • i-Level Media Group Inc. ILVL (3)
  • i2 Telecom International Inc. ITUI (7)
  • iB3 Networks Inc. IBNW (1)
  • IceWEB Inc. IWEB (5)
  • ICP Solar Technologies Inc. ICPR (3)
  • IDGLOBAL Corp. IDGJ (2)
  • IDO Security Inc. IDOI (22)
  • IFAN Financial Inc. IFAN (34)
  • iGambit, Inc. IGMB (5)
  • Imaging3 Inc. IMGG (2)
  • ImaRx Therapeutics Inc. IMRX (2)
  • Immune Therapeutics Inc. IMUN (11)
  • Impact E-Solutions Corp. IESO (1)
  • Imperial Petroleum Inc. IPMN (10)
  • Inca Designs Inc. IDGI.PK (4)
  • Independent Film Development Corp. IFLM (1)
  • Index Oil and Gas Inc. IXOG.OB (5)
  • India Globalization Capital, Inc. IGC (21)
  • Industrial Biotechnology Corp. IBOT (1)
  • Infinite Group Inc. IMCI (48)
  • Inform Worldwide Holdings, Inc. IWWI (27)
  • InMed Pharmaceuticals, Inc. IMLFF (35)
  • Intec LTD ICLJY (1)
  • IntegraMed America Inc INMD (1)
  • Intelecom Inc. IECM (3)
  • Intelimax Media Inc. IXMD (31)
  • Intelligent Highway Solutions Inc. IHSI (6)
  • Intercept Energy Services Inc. IESCF (7)
  • Interleukin Genetics Inc. ILI (1)
  • International Barrier Technology Inc IBTGF (1)
  • International Consolidated Companies Inc. INCC (2)
  • International Stem Cell Corp. ISCO (226)
  • Inventergy Global Inc. INVT (15)
  • Investor Village (9)
  • Investors Business Daily (4)
  • InvestorsProfs (1)
  • InvestSource (11)
  • IPOs (8)
  • IR Biosciences Holdings Inc IRBS (3)
  • Isonics Corp. ISON (1)
  • ItsAboutFinance (2)
  • JC Data Solutions Inc. JCDS (4)
  • Joytoto USA Inc. JYTO (14)
  • JZZ Technologies Inc. JZZI (3)
  • KAL Energy Inc. KALG (3)
  • Kallo Inc. KALO (43)
  • Kandi Technologies Corp. KNDI (3)
  • KCM Holding Corp. KCMH (3)
  • Kingslake Energy Inc. KGLJ (2)
  • Klondex Mines Ltd. KLNDF (1)
  • Knobias KNBS (5)
  • Kootenay Zinc Corp. KTNNF (12)
  • Kraig Biocraft Laboratories Inc. KBLB (88)
  • L&L International Holdings Inc. LLFH (2)
  • Laguna Blends Inc. LAGBF (53)
  • Lantis Laser Inc. LLSR (5)
  • Last Mile Logistics Group LMLG (4)
  • Latitude 360 Inc. LATX (21)
  • LD Holdings Inc. LDHL (14)
  • Legacy Holdings Inc. LGYH (1)
  • Legacy Ventures International Inc. LGYV (24)
  • Legend Media Inc. LEGE (4)
  • Lexaria Bioscience Corp. LXRP (36)
  • Lifespan Inc. LSPN (1)
  • Lime Energy Corp. LIME (3)
  • Lingo Media Corp. LMDCF (18)
  • Linkwell Corporation LWLL (4)
  • Liquor Group Wholesale Inc. LIQR (22)
  • Loans4Less.com Inc. LFLS (47)
  • LOGIC Devices Inc. LOGC (1)
  • Logility Inc. LGTY (1)
  • LoJack Corp LOJN (3)
  • Longhai Steel Inc. LGHS (10)
  • LottoGopher Holdings Inc. LTTGF (18)
  • Lotus Pharmaceuticals Inc. LTUS (1)
  • Low Carbon Technologies (LWCTF) (3)
  • Lucas Energy, Inc. LEI (17)
  • Mabwe Minerals Inc. MBMI (56)
  • Macquarie Infrastructure Company MIC (5)
  • Maine and Maritime Corp. MMA (1)
  • Majic Wheels Corp. MJWL (6)
  • Makeup Inc. MAKU (2)
  • Mammoth Energy Group Inc. MMTE (5)
  • Mantra Venture Group Ltd. MVTG (10)
  • Marijuana Company of America, Inc. MCOA (11)
  • Mariner’s Choice International Inc. MCII (2)
  • Martin Nutraceuticals MNIU (11)
  • Material Technologies Inc. MTCH (44)
  • Max Media Group Inc. MXMI (9)
  • Max Sound Corp. MAXD (30)
  • MC Endeavors Inc. MSMY (2)
  • MedeFile International Inc. MDFI (46)
  • MediaG3 Inc. MDGC (1)
  • Medical Cannabis Payment Solutions (REFG) (1)
  • Medical Cannabis Payment Solutions REFG (2)
  • Medical Innovation Holdings, Inc. MIHI (9)
  • Medical Transcription Billing Corp. MTBC (13)
  • Medina International Holdings Inc. MIHI (3)
  • Medisafe 1 Technologies Corp. MFTH (3)
  • Medivisor Inc. MVSR (1)
  • Mega Media Group, Inc. MMDA (30)
  • MegaWest Energy Corporation MGWSF (2)
  • Memry Corp. MRY (2)
  • Metro One Development Inc. MODI (2)
  • Mexico Energy Corp. MXC (1)
  • MGX Minerals, Inc. MGXMF (12)
  • Micro Identification Technologies Inc. MMTC (44)
  • MicrocapMoney (2)
  • Microsoft Corporation MSFT (4)
  • Midway Gold Corp. MDW (1)
  • Military Resale Group MYRL (19)
  • Minco Silver Corp. MSV.TO (1)
  • Mindpix Corp. MNDP (1)
  • MIP Solutions Inc. MSOL (7)
  • MIT Holding MITD (36)
  • MitoPharm Corp. MTPH (1)
  • Mizati Luxury Alloy Wheels, Inc. MZTI (14)
  • Mobile Entertainment Inc. MBEI (1)
  • Mobile Lads Corp. MOBO (43)
  • Momentous Entertainment Group Inc. MMEG (19)
  • Monaker Group Inc. MKGI (48)
  • Money4Gold Holdings Inc. MFGD (3)
  • MortgageBrokers.com Holdings Inc. MBKR (2)
  • Mosquito Consolidated Gold Mines Limited MSQ.V (1)
  • Moxian Inc. MOXC (62)
  • mPhase Technologies Inc. XDSL (12)
  • MSE Enviro-Tech Corp. MEVT (4)
  • Muscle Flex Inc. MFLI (55)
  • MusclePharm Corp. MSLP (23)
  • Mvive Inc. MVIV (22)
  • My Automated Advisor (4)
  • MyECheck Inc. MYEC (99)
  • MyStaru.com Inc. MYST (1)
  • Nanogen Inc. NGEN (2)
  • Nanometrics Inc. NANO (1)
  • NanoSensors Inc. NNSR (1)
  • NanoTech Entertainment Inc. NTEK (30)
  • Napster, Inc. NAPS (5)
  • National Automation Services Inc. NASV (67)
  • National Coal Corp. NCOC (2)
  • National Waste Management Holdings Inc. NWMH (24)
  • Naturally Iowa Inc. NLIA (2)
  • NavStar Technologies Inc. NVSR (16)
  • nCoat Inc NCOA (8)
  • Neah Power Systems NPWZ (14)
  • Neohydro Technologies Corp. NHYT (4)
  • Neoprobe Corp. NEOP (6)
  • NeoStem Inc. NBS (6)
  • Net Element Inc. NETE (19)
  • NetSol Technologies Inc NTWK (64)
  • Neurobiological Technologies Inc. NTII (3)
  • NeuroMama Ltd. NERO (15)
  • Neutra Corp. NTRR (37)
  • New Asia Gold Corp. NWAG (1)
  • New Generation Biofuel Holdings Inc. GNB (3)
  • NewMarket China Inc. NMCH (7)
  • NewMarket Technology Inc. NMKT (7)
  • Newport Digital Technologies Inc. NPDT (61)
  • Nexia Holdings Inc. NXHD (51)
  • NexMed Inc. NEXM (8)
  • NeXplore Corp. NXPC (4)
  • Next One Interactive Inc. NXOI (7)
  • NextGen Bioscience Inc. NXGB (1)
  • NextPhase Wireless Inc. NPHS (1)
  • Nexus Enterprise Solutions Inc. NXES (30)
  • NF Energy Saving Corp. of America NFES (1)
  • Nhale Inc. NHLE (18)
  • Nilam Resources Inc. NILR (4)
  • Nitro Petroleum Inc. NTRO (5)
  • North Bay Resources Inc. NBRI (10)
  • NuTech Inc. NTCI (1)
  • Nutra Pharma Corp. NPHC (21)
  • NutraNomics Inc. NNRX (30)
  • NuVim Inc. NUVM (1)
  • NVIDIA Corp. NVDA (1)
  • NXGen Holdings Inc. NXGH (1)
  • Oakridge Global Energy Solutions Inc. OGES (63)
  • Obee's Franchise Systems Inc. OBFM (1)
  • OBJ Enterprises Inc. OBJE (27)
  • Odyne Corporation ODYC (15)
  • Omega Commercial Finance Corp. OCFN (2)
  • OmniaLuo Inc. OLUO (1)
  • Omnicity Corp. OMCY (26)
  • Omninet Media.Com, Inc. ONMC (5)
  • On The Go Healthcare Inc. MODI (13)
  • On the Move Systems Inc. OMVS (102)
  • Oncolin Therapeutics Inc. OCOL (1)
  • One Step Vending Corp. KOSK (2)
  • One World Holdings Inc. OWOO (61)
  • Ones to Watch (1,353)
  • Onstream Media Corp. ONSM (5)
  • Onteco Corp. ONTC (4)
  • Open Energy Corp. OEGY (4)
  • Optical Systems Inc. OPSY (2)
  • Oramed Pharmaceuticals Inc. ORMP (2)
  • Organic Alliance Inc. ORGC (2)
  • ORHub, Inc. ORHB (26)
  • OTCPicks.com (82)
  • OtcStockExchange (5)
  • OurPet's Company OPCO (78)
  • OxySure Systems Inc. OXYS (23)
  • P2 Solar Inc. PTOS (24)
  • Pacific Gold Corp. PCFG (3)
  • Pamplona Picks (1)
  • Pan Global Corp. PGLO (82)
  • PanGenex Corp. PGCX (3)
  • Paramount Gold and Silver Corp. PZG (3)
  • Patient Access Solutions Inc. PASO (7)
  • Patriot Energy Corp. dba TelTeck Solutions Inc PGYC.PK (11)
  • Patriot One Technologies, Inc. PTOTF (24)
  • Patriot Scientific Corp. PTSC (6)
  • Peace Arch Entertainment Group Inc. PAE (1)
  • Peoples Educational Holdings Inc. PEDH (2)
  • Perf Go Green Holdings Inc. PGOG (12)
  • Perfect Web Technologies, Inc PWBI (11)
  • Perfectenergy International Ltd. PFGY (1)
  • Performance Health Technologies Inc. PFMH (31)
  • Pet DRX Corp. VETS (1)
  • Petro Resources Corp. PRC (2)
  • PetroSun Inc. PSUD (41)
  • Petroteq Energy Inc. PQEFF (4)
  • Phantom Fiber Corp. PHFB (2)
  • Pilot Financial Communications (3)
  • Pipex Pharmaceuticals Inc. PP (2)
  • PITOOEY! Inc. PTOO (14)
  • Planet Nutrition Inc. PNHL (4)
  • Platina Energy Group Inc. PLTG (8)
  • PlayBOX Inc. PYBX (5)
  • Players Network PNTV (15)
  • Pluristem Therapeutics Inc. PSTI (10)
  • Positron Corp. POSC (3)
  • PotNetwork Holding, Inc. POTN (23)
  • Power of the Dream Ventures (1)
  • Power Play Development Corp. PWPY (17)
  • Powersafe Technology Corp. PWSF (1)
  • Premier Energy Corp. PNRC (1)
  • Pressure BioSciences Inc. PBIO (41)
  • PRG Group Inc. PRGJ (2)
  • PrimEdge Inc. PEDI (1)
  • Private Equity Securities (93)
  • Pro Motors Group Corp. PMGU (2)
  • Pro Travel Network Inc. PTVL (2)
  • ProBility Media Corp. PBYA (33)
  • ProGaming Platforms Corp. PPTF (22)
  • Proginet Corp. PRGF (3)
  • Prom Resources PRMO (9)
  • Propalms Inc. PRPM (3)
  • Provectus Pharmaceuticals Inc. PVCT (12)
  • Puget Technologies Inc. PUGE (23)
  • Pulmo BioTech Inc. PLMO (4)
  • Puramed Bioscience Inc. PMBS (3)
  • Pure Biofuels Corp. PBOF (4)
  • Pure H2O Inc. PURH (1)
  • Pure Hospitality Solutions Inc. PNOW (99)
  • Purio Inc. PURO (5)
  • Puritan Financial Group Inc. PTNG (1)
  • Purple Beverage Company Inc. PPBV (8)
  • QED Connect Inc. QEDC (4)
  • Qiao Xing Universal Telephone Inc. XING (2)
  • QPC Lasers Inc. QPCI (3)
  • Qualcomm Inc. QCOM (2)
  • QualityStocks for Women (16)
  • QualityStocks Partner StockGuru (3,878)
  • QualityStocks Stock Newsletter (551)
  • QualityStocks Stock Newsletters (18,172)
  • QualityStocks Video Charts (286)
  • QualityStocks.net Market Basics (6)
  • QualityStocksNewsBreaks (321)
  • Quantum Fuel Systems Technologies Worldwide Inc. QTWW (15)
  • Quantum International Corp. QUAN (3)
  • Quasar Aerospace Industries Inc. QASP (6)
  • QuoteMedia Inc. QMCI (120)
  • Rafarma Pharmaceuticals Inc. RAFA (31)
  • Rainbow Coral Corp. RBCC (33)
  • Rancher Energy Corp. RNCH (9)
  • Raptor Resources Holdings Inc. RRHI (50)
  • Raven Gold Corp. RVNG (3)
  • Red Lake Exploration Inc. RLKX (19)
  • RegalWorks Media Inc. RWMI (4)
  • Regenicin, Inc. RGIN (6)
  • Reliant Financial Services Inc. RFNS (1)
  • Renhuang Pharmaceuticals Inc. RHGP (3)
  • ReoStar Energy Corp. REOS (1)
  • Resort Savers Inc. (RSSV) (10)
  • Revett Minerals (1)
  • RJD Green Inc. RJDG (9)
  • Rock Energy Resources Inc. RCKE (4)
  • Rodman & Renshaw (432)
  • Ronn Motor Company Inc. RNNM (6)
  • Rox Resources Ltd. RXRS (3)
  • Royal Quantum Group, Inc. RYQG (10)
  • Royal Standard Minerals Inc. RYSMF (2)
  • Rudy Nutrition RUNU (27)
  • RXi Pharmaceuticals Corp. RXII (3)
  • Santa Fe Gold Corp. SFEG (5)
  • Santa Fe Holding Company SFHD (3)
  • Save The World Air Inc. ZERO (12)
  • Savoy Energy Corp. SNVP (26)
  • SavWatt USA, Inc. SAVW (5)
  • Seabridge Gold Inc. SA (1)
  • Seawright Holdings Inc. SWRI (1)
  • Sector 10 Inc. SECI (78)
  • SES Solar Inc. SESI (2)
  • Seven Arts Pictures plc SAPX (1)
  • Seven Arts Pictures PLC SAPXF (5)
  • Shazam Stocks (22)
  • ShotPak Inc. SHTP (35)
  • Shumate Industries SHMTE (1)
  • Sibling Group Holdings Inc. SIBE (55)
  • Sierra Gold Corp. SGCP (2)
  • Signature Devices Inc. SDVI (9)
  • Silver Dragon Resources Inc. SDRG (1)
  • Silver Falcon Mining Inc. SFMI (1)
  • SilverSun Technologies Inc. SSNT (30)
  • Simtrol Inc. SMRL (74)
  • Simulated Environment Concepts Inc. SMEV (130)
  • Singlepoint Inc. SING (113)
  • Sino Agro Food Inc. SIAF (1)
  • Sinobiomed Inc. SOBM (4)
  • Sinovac Biotech Ltd SVC (1)
  • Sipp Industries Inc. SIPC (2)
  • Skinny Nutritional Corp. SKNY (19)
  • Skinvisible, Inc. SKVI (10)
  • Sky Petroleum Inc. SKPI (1)
  • SkyPostal Networks Inc. SKPN (66)
  • Small Cap Sentinel (2)
  • Small Cap Sleeper (3)
  • Smallcap Bullets (2)
  • Smallcaps.us (22)
  • SmallCapVoice (428)
  • Smoky Market Foods Inc. SMKY (9)
  • SocialPicks (1)
  • Sofame Technologies Inc SDW.V (1)
  • Sohm Inc. SHMN (14)
  • Solanex Management Inc. SLNX (15)
  • Solar Energy Initiatives Inc. SNRY (14)
  • Solar Wind Energy Tower Inc. SWET (15)
  • Solarfun Power Holdings Co. Ltd. SOLF (2)
  • Soul and Vibe Interactive Inc. SOUL (14)
  • South Sea Energy Corp. SSGY (7)
  • Soyo Group Inc SOYO (2)
  • SpaceDev Inc. SPDV (5)
  • Sparta Commercial Services Inc. SRCO (31)
  • Speedemissions Inc. SPMI (14)
  • Spicy Pickle Inc SPKL (18)
  • SpongeTech Delivery Systems Inc. SPNG (14)
  • Sports Pouch Beverage Company Inc. SPBV (1)
  • Star Mountain Resources Inc. SMRS (37)
  • Start Scientific Inc. STSC (22)
  • Stealth Technologies, Inc. STTH (3)
  • Stock Market E-News (1)
  • Stock Promoters (4)
  • StockEgg (14)
  • Stocks to Watch (1,926)
  • StocksJournal (2)
  • StockUPTicks (165)
  • Stockwire (6)
  • Strategic American Oil Corp SGCA (32)
  • Stratos Renewables Corp. SRNW (89)
  • StreamTrack Inc. STTK (31)
  • Striker Oil & Gas Inc. SOIS (4)
  • Sun Motor International Inc. SNMO (1)
  • SUN Sports & Entertainment Inc. SSPE (3)
  • Sunshine Biopharma Inc. SBFM (6)
  • Superlattice Power Inc. SLAT (60)
  • SupportSave Solutions, Inc. SSVE (10)
  • Surefect Holdings Inc. SUFH (1)
  • Suspect Detection Systems Inc. SDSS (37)
  • Sweet Success Enterprises Inc. SWTS (35)
  • Swiss Hawk AG SWHKF (1)
  • Symposium Production Corp. SYPJ (1)
  • Tactical Air Defense Services, Inc. TADF (15)
  • Tao Minerals Ltd. TAOL (1)
  • TapImmune, Inc. TPIV (15)
  • Tapinator, Inc. TAPM (10)
  • Taplmmune Inc. TPIM (1)
  • Technology Applications International Inc. NUUU (25)
  • TechPrecision Corp. TPCS (4)
  • Tecton Corp. TTNC (3)
  • Teknik Digital Arts Inc. TKNK (10)
  • Telanetix Inc. TNXI (2)
  • Teletouch Communications Inc. TLLE (5)
  • Terax Energy Inc. TEXG (32)
  • Terme Bancorp TMEB (1)
  • Terra Nostra Resources Corp. TNRO (25)
  • The Amergence Group AMNG (8)
  • The Aristocrat Group Corp. ASCC (113)
  • The Bowser Report (68)
  • The Bull Report (32)
  • The Capital Report (5)
  • The DIRECTV Group Inc. DTV (1)
  • The Fight Zone Inc. TFZI (12)
  • The Green Organic Dutchman Holdings Ltd. TGOD (3)
  • The Guitammer Company Inc. GTMM (38)
  • The International Traders Expo (30)
  • The Mobile Star Corp. MBST (7)
  • The Motley Fool (3)
  • The Mundus Group Inc. MNDS (1)
  • The Penny Stock Blog (28)
  • The Principal Structure Fund, Inc. PSF (2)
  • The Tracking Corp. TRKG (1)
  • The UpTurn, Inc. UPTR (20)
  • The Wall Street Savant (24)
  • The Wide Angle (3)
  • Thresher Industries Inc. THRR (15)
  • Tidelands Oil and Gas Corp. TIDE (1)
  • Tiens Biotech Group USA Inc. TBV (1)
  • TMT Capital Corp. TMTP (1)
  • TNI BioTech Inc. TNIB (16)
  • Tombstone Exploration Corp. TMBXF (9)
  • TOMI Environmental Solutions Inc. TOMZ (4)
  • Tootie Pie Company, Inc. TOOT (11)
  • Torchlight Energy Resources, Inc. TRCH (2)
  • TradeShow Marketing Company Inc. TSHO (21)
  • TransWorldNews (4)
  • Tri-Star Holdings Inc. TSHL (31)
  • Trimax Corp. TMXN (31)
  • TripleCrownStocks (9)
  • True 2 Beauty Inc. TRTB (43)
  • TwinTrader (8)
  • TXP Corporation TXPO (1)
  • TZ Ltd. TZL.AX (1)
  • U.S. Mine Makers Inc. USMM (1)
  • uKarma Corporation UKMA (1)
  • Ultitek Ltd. UITK (21)
  • Unbridled Energy Corporation TSX-UNE (21)
  • Unico Inc. UNCO (3)
  • Universal Bioenergy Inc. UBRG (3)
  • Universal Detection Technology UNDT (41)
  • Universal Energy Corp. UVSE (19)
  • Universal Property Development and Acquisition UPDA (4)
  • Universal Tracking Solutions Inc. UTRK (13)
  • Universal Travel Group UTVG (14)
  • UpSNAP Inc. UPSN (1)
  • Uranium Energy Corp. UEC (64)
  • Uranium Hunter Corp. URHN (17)
  • Urex Energy Corp. URXE (1)
  • USA Recycling Industries Inc. USRI (21)
  • USA Superior Energy Inc. USSU (9)
  • Ustelematics Inc. UTLM (27)
  • Utah Uranium Corp. UTUC (2)
  • Utilicraft Aerospace Industries Inc. UITA (2)
  • ValueRich & iValueRich (9)
  • Vaporin Inc. VAPOD (2)
  • VentriPoint Diagnostics Ltd. VPTDF (26)
  • Vermillion Inc. VRML (3)
  • Vertical Branding Inc. VBDG (11)
  • VIASPACE, Inc. VSPC (185)
  • Victory Energy Corp. VYEY (29)
  • Vidshadow Inc. VSHD (1)
  • View Systems Inc. VSYM (16)
  • Viper Networks Inc. VPER (2)
  • Viral Genetics Inc. VRAL (3)
  • Viropro International Inc. VPRO (2)
  • VirTra Systems Inc. VTSI (22)
  • Viscount Systems Inc. VSYS (27)
  • visionGATEWAY Inc. VGWA (1)
  • VistaGen Therapeutics Inc. VSTA (104)
  • Visualant Inc. VSUL (5)
  • Vital Products Inc. VTLP (5)
  • Viyya Technologies Inc. VYON (2)
  • VizStar Inc VIZS (24)
  • Voiceserve Inc. VSRV (18)
  • Vortex Resources Corp. VTEX (7)
  • Vsurance Inc. VSUR (3)
  • Vyteris Inc. VYHN (1)
  • W2 Energy Inc. WWEN (13)
  • Wall Street News Alert (76)
  • WallStreetGrapevine (12)
  • WaterPure International Inc. WPUR (4)
  • Wave Systems Corp. WAVX (5)
  • Week in Review (2)
  • Well Power Inc. WPWR (77)
  • Wescorp Energy Inc. WSCE (18)
  • West Canyon Energy Corp. WCYO (1)
  • Western Standard Energy Corp. WSEG (7)
  • Who's Your Daddy Inc. WYDI (7)
  • WikiLoan Inc. WKLI (14)
  • Wind Energy America Inc. WNEA (3)
  • Wisdom Homes of America Inc. WOFA (15)
  • Wits Basin Precious Minerals Inc. WITM (2)
  • Woize International Ltd. WOIZ (1)
  • WordLogic Corp. WLGC (40)
  • Workstream Inc. WSTM (9)
  • WorldWater & Solar Technologies Corp. WWAT (10)
  • Worldwide Energy and Manufacturing WEMU (12)
  • Worldwide Manufacturing USA Inc. WWMU (6)
  • WRIT Media Group Inc. WRIT (36)
  • X-Change Corp. (XCHC) (2)
  • Xaar Plc XAARF (1)
  • Xenomics Inc. XNOM (1)
  • XsunX Inc. XSNX (17)
  • XZERES Corp. XPWR (2)
  • Younger America YNGR (13)
  • Zacks Investment Research (11)
  • ZAGG Inc. ZAGG (9)
  • Zaldiva Inc. ZLDV (3)
  • ZAP ZAAP (15)
  • ZBB Energy Corp ZBB (7)
  • Zenosense Inc. ZENO (53)
  • Zentric Inc. ZNTR (14)
  • Zevotek Inc. ZVTK (8)
  • Zinc One Resources Inc. ZZZOF (3)
  • Znomics Inc. ZNOM (3)
  • Newsletter Signup

    Stay ahead of the pack with QualityStocks and receive "The QualityStocks Daily", our summary formatted newsletter containing stock tips from hundreds of online investment newsletters.

    Rotate your device 90° to view site.